Sugi Predict

Sugi Predict / Compounds / SCHEMBL12834985

SCHEMBL12834985

SCHEMBL12834985

Cc1ccc(OCC2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.80

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 10/20 0.58
▸ CHEK2 O96017 1/20 0.55
▸ KMT2A Q03164 1/20 0.54
▸ CSF1R P07333 1/20 0.52
▸ KDM4E B2RXH2 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ GRIN2B Q13224 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ HDAC1 Q13547 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18842715 0.96 GPR119 (0.57) GPR119CHEK2KMT2AHDAC1
SCHEMBL15412759 0.90 GPR119 (0.58) GPR119CHEK2KDM4EPKMHDAC1
SCHEMBL3256200 0.89 GPR119 (0.57) GPR119CHEK2KMT2AKDM4EPKM
SCHEMBL1769099 0.89 GPR119 (0.57) GPR119CHEK2KMT2AKDM4EPKM
SCHEMBL2456170 0.89 GPR119 (0.57) GPR119CHEK2KDM4EPKMHDAC1
SCHEMBL213773 0.89 GPR119 (0.57) GPR119CHEK2KDM4EPKMHDAC1
SCHEMBL15495771 0.88 GPR119 (0.49) GPR119CHEK2KMT2AKDM4ETP53
SCHEMBL3249170 0.88 KDM4E (0.61) GPR119CHEK2CSF1RKDM4EPKM
SCHEMBL3096959 0.88 GPR119 (0.67) GPR119CHEK2
SCHEMBL17078731 0.88 GPR119 (0.56) GPR119CHEK2KDM4EPKMHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116648248-B Aromatic compound, pharmaceutical composition containing same and application thereof 成都茵创园医药科技有限公司 2025-04-15 — — CN disclosed
CN-118344384-A Compounds and uses thereof 丹诺医药(苏州）有限公司 2024-07-16 — — CN disclosed
CN-116648248-A Aromatic compound, pharmaceutical composition containing same and application thereof 成都茵创园医药科技有限公司 2023-08-25 — — CN disclosed
WO-2022161414-A1 AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATION THEREOF 成都茵创园医药科技有限公司 2022-08-04 — — WO disclosed
US-9776987-B2 Amide derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2017-10-03 — — US disclosed
US-20170129875-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-05-11 — — US disclosed
EP-1957498-B1 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING METHYLGENE INC (CA) 2017-02-15 — — EP disclosed
US-8372860-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-12 — — US disclosed
CN-101123964-B G-protein coupled receptor (GPR116) agonists and pharmaceutical compositions comprising the same PROSIDION LTD 2012-11-28 — — CN disclosed
EP-2298304-A2 Carboline derivatives useful in the treatment of cancer PTC Therapeutics, Inc. (US) 2011-03-23 — — EP disclosed
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS PTC THERAPEUTICS, INC. 2010-07-15 — — US disclosed
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2010-06-24 — — US disclosed
US-7601840-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2009-10-13 — — US disclosed
WO-2008127714-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. (US) 2008-10-23 — — WO disclosed
WO-2008127715-A1 CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. (US) 2008-10-23 — — WO disclosed
CN-101123964-A G-protein coupled receptor (GPR116) agonists and their use for the treatment of obesity and diabetes PROSIDION LTD (GB) 2008-02-13 — — CN disclosed
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration PCT THERAPEUTICS, INC. (US) 2007-12-06 — — US disclosed
CN-1267431-C Substituted quinazoline derivatives and their use as inhibitors ASTRAZENECA AB (SE) 2006-08-02 — — CN disclosed
CN-1496364-A Substituted quinazoline derivatives and their use as inhibitors — 2004-05-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES RNMT, VEGFA, VHL GPR119 1857/4885CHEK2 1665/4885KMT2A 1179/4885
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration VEGFA, FLT4, MIF GPR119 34/4885CHEK2 4414/4885KMT2A 3947/4885
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS VEGFA, FLT4, PGF GPR119 2377/4885CHEK2 2883/4885KMT2A 929/4885
US-20170129875-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST GPR119, FFAR2, GLP1R GPR119 1/4885CHEK2 3508/4885KMT2A 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.